The findings further suggest that ERRFI1 mutations leading to the deletion of segment 1/2 domains or impaired Y394/Y395 phosphorylation may serve as a key genomic alteration associated with GBM development, especially in the context of specific genetic backgrounds such as EGFR amplification (Note that raw images of immunoblotting data are displayed in Figs S7–S11). The gene discussed is EGFR; the disease is glioblastoma.